Systemic treatment options available for HER2+ metastatic breast cancer based on recent clinical trial data and abstract presentations from the ASCO 2021 virtual meeting.
EP. 1: Current Standard of Care for HER2+ MBC
Current treatment approaches available to treat HER2-positive metastatic breast cancer in the first- and second-line treatment settings.
EP. 2: The HER2CLIMB Study in HER2+ MBC
The significance of the HER2CLIMB study of tucatinib in combination with capecitabine and trastuzumab as treatment for patients with HER2-positive metastatic breast cancer.
EP. 3: Implications of DESTINY-Breast01 in HER2+ MBC
Considerations for initiating trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer who received previous treatment with trastuzumab emtansine based on data demonstrated by the DESTINY-Breast01 study.
EP. 4: Updates in HER2+ MBC: The NALA and SOPHIA Trials
Dr Lee Schwartzberg, MD, FASCO, highlights the appropriateness for treating HER2-positive metastatic breast cancer with either neratinib plus capecitabine or margetuximab plus chemotherapy based on evidence revealed by the NALA and SOPHIA clinical trials.
EP. 5: Safety Profiles of Systemic Therapies for HER2+ MBC
Best practices for preventing and managing treatment-related adverse events associated with systemic therapies used to treat HER2-positive metastatic breast cancer.
EP. 6: Subcutaneous Therapy for HER2+ Breast Cancer
Breast oncologists discuss the pros and cons of treating patients with HER2-postive breast cancer with the fixed-dose subcutaneous formulation of pertuzumab plus trastuzumab compared with IV chemotherapy.
EP. 7: Individualized Treatment Decisions for HER2+ Breast Cancer
Variables that breast oncologists need to consider when selecting an appropriate systemic treatment approach for a patient with HER2-positive breast cancer.
EP. 8: Relapsed/Refractory HER2+ MBC Treatment Decisions
Options available to treat patients with HER2-positive metastatic breast cancer following frontline therapy with T-DM1.
EP. 9: Brain Metastasis in HER2+ MBC
Recommendations for screening patients with HER2-positive metastatic breast cancer for signs of brain metastasis as a consequence of current rates of prevalence.
EP. 10: Treatment Options for HER2+ MBC With Brain Metastasis
Options available to treat patients with HER2-positive metastatic breast cancer and brain metastasis, and factors that impact choice of therapy based on CNS data demonstrated in several clinical trials of HER2-targeted agents.
EP. 11: Case Scenario: 55-Year-Old Woman With HER2+ MBC and Brain Metastasis
A discussion regarding the preferred treatment approach for a 55-year-old woman with HR-/HER2+ metastatic breast cancer and 2 brain metastases.
EP. 12: Gaps in Treatment for HER2+ MBC With Brain Metastasis
Considerations for addressing gaps in treatment for patients with HER2-positive metastatic breast cancer and brain metastasis, based on recent trial data.
EP. 13: Frontline Therapy for Triple-Positive Breast Cancer
Vijayakrishna Gadi, MD, PhD, defines triple-positive breast cancer and reacts to the potential use of trastuzumab combined with endocrine therapy as frontline therapy.
EP. 14: Emerging Combinations for Triple-Positive Breast Cancer
An overview of various trials investigating combination approaches as frontline therapy for triple-positive breast cancer and considerations for when to use chemotherapy and bring endocrine therapy into treatment.
EP. 15: Immunotherapy for HER2+ Breast Cancer
The rationale for incorporating checkpoint inhibitors into treatment regimens for HER2-positive breast cancer.
EP. 16: Emerging Therapies for HER2+ MBC
An overview of therapies under study in later-stage clinical trials to treat HER2-positive metastatic breast cancer.
EP. 17: Using Systemic Therapy to Treat HER2+ Breast Cancer
Closing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.